Need help? +44 (0) 7457 418426

MEDICINE DETAILS

Elrexfio

Active ingredient: Elranatamab Bcmm

Neutral reference profile for an independent medicine-access consultancy enquiry about Elrexfio (Elranatamab Bcmm). No medicine is offered for sale.

NEXT STEP

Choose the strength and pack

✓ If you are unsure, choose “I do not know”.

These options are not medical advice, a dosing recommendation, stock confirmation or a sale offer.

ABOUT THIS MEDICINE

What is Elrexfio used for?

Elrexfio (elranatamab-bcmm) is a prescription medicine for adult patients with multiple myeloma who:

  • have received at least four prior treatments, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody;
  • AND their cancer has come back or not responded to treatment.

Elrexfio is available as a subcutaneous injection in these strengths:

  • 76 mg/1.9 mL;
  • 44 mg/1.1 mL.

This information is general and is not medical advice. Talk to your doctor or pharmacist about any treatment decision.

RECORDED PRODUCT PROFILE

Elrexfio identity, dosage form and pack information.

The details below are assembled from current catalogue records. They must still be checked against the prescription, medicine box and an official regulatory record.

Brand recordElrexfio
Active ingredientElranatamab Bcmm
Dosage formsolution for injection
Recorded options2
Directory areaOncology
Catalogue synchronised

Recorded strength and pack options

Each row is shown only to help identify the product; it is not stock confirmation or a sale offer.

  1. 40 mg/ml (44 mg total) · 1 vial (1.1 ml) Catalogue organisation: Pfizer Pharma GmbH
  2. 40 mg/ml (76 mg total) · 1 vial (1.9 ml) Catalogue organisation: Pfizer Pharma GmbH

OFFICIAL SOURCES

Check the Elrexfio record at an official source.

Search for “Elrexfio” or “Elranatamab Bcmm”. Finding a product in one source does not by itself confirm stock, authorisation in a particular country or suitability for a patient.

SERVICE BOUNDARY

Information checking and independent enquiry support for Elrexfio.

OrphanDrug helps organise the product identity and recorded strength and pack details for an enquiry. It does not sell, take payment for, prescribe, import, dispense or deliver medicines.

Clinical decision: Only a qualified healthcare professional who has assessed the patient can decide whether a product, form or dose is appropriate.

CLEAR ANSWERS

Frequently asked questions about Elrexfio

01What is Elrexfio?

This directory record associates the brand name Elrexfio with the active ingredient Elranatamab Bcmm. The brand and ingredient are shown for product identification only, not as treatment or dosing advice.

02Which Elrexfio strengths and packs are recorded?

The catalogue currently shows: 40 mg/ml (44 mg total) · 1 vial (1.1 ml); 40 mg/ml (76 mg total) · 1 vial (1.9 ml). Check the complete strength, dosage form and pack description against the prescription and medicine box.

03Who manufactures Elrexfio?

Catalogue records currently name: Pfizer Pharma GmbH. This field may identify a manufacturer, marketing-authorisation holder, marketing company or supplier; confirm the exact role on the pack leaflet and official regulatory record.

04Do the listed options confirm stock or access?

No. A catalogue record does not confirm current stock, authorisation in a particular country, clinical suitability, import permission or access.

05What affects a possible estimated medicine cost for Elrexfio?

A possible cost depends on the exact strength, dosage form, pack, quantity, destination and regulatory jurisdiction. Any amount provided after an enquiry is an indicative medicine-cost estimate only, not a selling price for Elrexfio, payment request, stock guarantee or binding offer.

06Can I buy Elrexfio from this website?

No. This website does not sell, take payment for, prescribe, import, dispense or deliver medicines. The form creates an independent consultancy enquiry only.